| Name | Title | Contact Details |
|---|
Public Risk Innovation, Solutions, and Management, PRISM, is a member-directed risk sharing pool of counties and public entities committed to providing risk coverage programs and risk management services.
Cobalt Sports Holdings was created to provide support, opportunities, collaboration and revenue streams to sports programs by combining the strength in numbers philosophy with clubs that are independent by structure and desire. These are sports programs that want to: Remain independent yet want to build programs that can retain players and coaches Compete at the highest levels Create exposure for players Be relevant at the local, state and national level events Continue to grow within their community. At Cobalt, we believe that EVERY club and EVERY player is relevant. That EVERY club deserves to thrive and that EVERY player should have multiple pathways as well as high-level coaching education opportunities. Pathways to the pros and pathways to college soccer. By combining like minded leaders running independent programs, a superior community of offerings is available to our members.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.